ArticleFrontiers in medicine2026
Nomogram based on computed tomography fractal dimension for predicting spread through air spaces in lung adenocarcinoma.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to develop and validate a CT-based nomogram incorporating three-dimensional fractal dimension (FD 3D) to noninvasively predict tumor spread through air spaces (STAS) in stage IA lung adenocarcinoma. Materials and methods: A retrospective analysis was performed on 110 patients with stage IA lung adenocarcinoma who underwent surgical resection. CT morphological features and fractal-dimension metrics were collected. Patients were categorized into STAS-positive ( Results: Univariate analysis showed significant differences in consolidation-to-tumor ratio (CTR) ( Conclusion: The CT-based nomogram integrating FD 3D and key imaging features can noninvasively predict STAS status in stage IA lung adenocarcinoma. This model shows promise for assisting surgical decision-making, though prospective studies are needed to validate its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.